Short Communication

Monkeypox and spillover effects: Stigmas, solutions and strategies

Hamna Raheel a, Maham Raheel b,*, Muhammad Ahmed Ali Fahim a, Unaiza Naeem a

a Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
b Department of Internal Medicine, Ziauddin University, Karachi, Pakistan

The Human Monkeypox virus, first identified in the 1970s in Congo during the smallpox surge [1] and endemic in Western and Central Africa, has had recent outbreaks in countries including United States of America (USA), Singapore, United Kingdom (UK), and Israel owing to travelers and imported animals from endemic regions [2–4]. On May 21st, the World Health Organization (WHO) reported 28 cases of monkeypox in non-endemic countries. This announcement stirred the medical community, which was left to grapple with the spread of yet another spillover infection. As of July 22nd, 2022, the centers for disease control and prevention (CDC) has reported 16,836 cases in 65 nations, with the most of them being recorded in Spain, Canada, UK, Northern Ireland, Germany and the US [5].

A member of the poxvirus family of Orthopoxviruses and a close relative to variola (the causative agent for smallpox), monkeypox’s transmission route includes respiratory droplets, skin-to-skin contact, contact with virus-infected fomites and oral fluid interactions that may occur during sexual contact [6]. In the early stages of infection, common signs and symptoms parallel that of the flu (fever, chills and myalgias), soon followed by swollen lymph nodes (near the groin and armpit areas) and a centrifugally spreading rash that initially presents as flat and dry, forming scabs that fall off.

The Food and Drug Association (FDA) has approved one vaccine as prophylactic treatment for the virus: Jynneos®® (MVA-BN) comprising of an attenuated virus and stipulated as 2 doses to be given 28 days apart. Another vaccine, ACAM2000®, previously used for smallpox and constitutes a live replicative virus, is also currently being used to vaccinate individuals [7]. Although evidence regarding Jynneos’s effectiveness is limited as animal models have been used during its research, WHO and CDC, citing observational studies from Africa, have approved the vaccine. These studies delineate the smallpox vaccines to be 85% effective in preventing monkeypox [8,9]. Moreover, some antiviral medications greenlit for emergency use by the FDA include tecovirimat and brincidofovir [10]. Tecovirimat acts by inhibiting the viral envelope protein p54, preventing the virus from leaving infected cells after it has replicated while brincidofovir, inhibits the viral DNA polymerase and prevents the virus from replicating. In a retrospective research conducted in UK, four individuals suspected of monkeypox were given brincidofovir (300 mg orally once a week), while one patient was given tecovirimat (600 mg twice a week orally) [11]. The results demonstrated that brincidofovir group patients exhibited markers pertaining to impaired liver function with no association between dose and reduction in clinical or viral parameters and displayed poor efficacy overall. Contrastingly, tecovirimat use results in decreased viral shedding from the upper respiratory tract, a shorter duration of symptoms, and no adverse effects.

The infection disproportionately affects people who identify as men having sex with men (MSM) [12]. According to a Euro surveillance survey in Spain, 93% of Monkeypox patients identified as MSM [13]. Of these, 84% reported having intercourse with multiple partners 21 days prior to the onset of symptoms. Stigma surrounding high-risk groups like MSM makes it tedious to identify such a population. In addition to health care disparities, MSM individuals are likely to present with comorbidities, namely HIV, which can undermine vaccine uptake due to an immunocompromised state [14]. Moreover, some cases of monkeypox manifest with a rash near the genitals and no flu-like symptoms, causing clinicians to frequently overlook and misdiagnose monkeypox as other sexually transmitted infections (STI) [15]. The largest study on monkeypox to date, identified single genital lesions, to be the major differentiator from (STI); in the additional symptoms noted 73% had anogenital lesions and 41% had mucosal lesions [16].

Vaccination programs confront a non-exhaustive list of challenges. Vaccine phobia, limited vaccine uptake among high-risk individuals, and vaccine scarcity in endemic areas, is attributed to disrupting mass immunization efforts. Nevertheless, attempts have been made to ring-vaccinate people vulnerable to contracting monkeypox and those in close contact with a suspected or confirmed case. With the vaccine demand exceeding supply in the US, it is only a matter of time when resource poor countries would also join the race to procure vaccines.

The COVID-19 pandemic should be a pressing reminder for the...
health sector to act promptly against monkeypox transmission. The virus’s spread through respiratory droplets should not be underestimated when compared to the aerosol droplet spread of COVID-19. Appropriate measures to quickly isolate and quarantine patients presenting with symptoms is a compelling need [17]. A spill-over infection like monkeypox is highly virulent with subsequent mutations surfacing, monitoring its epidemiology henceforth is imperative. Establishing a global open-access database like the Global health GitHub repository can be a possible method. Developed countries must deploy experts in areas open-access database like the Global health GitHub repository can be a possible method. Developed countries must deploy experts in areas

Ethical approval

This paper did not involve patients, therefore no ethical approval was required.

Sources of funding

None.

Author contributions

Hanna Raheel = conception of the study, drafting of the work, final approval and agreeing to the accuracy of the work.

Maham Raheel = conception of the study, drafting of the work, final approval and agreeing to the accuracy of the work.

Muhammad Ahmed Ali Fahim = conception of the study, drafting of the work, final approval and agreeing to the accuracy of the work.

Unaiza Naem = conception of the study, drafting of the work, final approval and agreeing to the accuracy of the work.

Registration of research studies

1. Name of the registry: Not applicable.
2. Unique identifying number or registration ID: Not applicable.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): Not applicable.

Guarantor

Hamna Raheel, Maham Raheel, Muhammad Ahmed Ali Fahim, Unaiza Naem.

Consent

This study was not done on patients or volunteers, therefore no written consent was required.

Declaration of competing interest

None.

References

[1] A.W. Rimoin, P.M. Mallembakani, S.C. Johnston, J.O. Lloyd Smith, N.K. Kikulu, T.L. Kinkela, et al., Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo, Proc. Natl. Acad. Sci. U.S.A. 107 (37) (2010) 16626-16627.
[2] O.T. Ng, V. Lee, K. Marinimuthu, S. Vassou, G. Chan, R.T.P. Lin, et al., A case of imported Monkeypox in Singapore, Lancet Infect. Dis. 19 (11) (2019) 1166.
[3] K.D. Reed, J.W. Melski, M.B. Graham, R.L. Regney, M.J. Sorit, M.V. Wegner, et al., The detection of monkeypox in humans in the western hemisphere. Emerg. Infect. Dis. 2004, 350, 4, 342, 350.
[4] N. Erer, H. Achoud, E. Milrot, Y. Schwartz, Y. Wiener-Goldhirsh, N. Paran, et al., Diagnosis of imported monkeypox, Israel, 2018, Emerg Infect Dis. J. 25 (5) (2019) 990.
[5] 2022 Monkeypox Outbreak Global Map [Internet]. 2022 [cited 24th July 2022]. Available from: https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html.
[6] K. Walter, P.N. Musau, What is monkeypox? JAMA 328 (3) (2022) 293.
[7] CDC, Monkeypox and Smallpox Vaccine Guidance, 2022 [Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html.
[8] Monkeypox [Internet]. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox.
[9] Considerations for Monkeypox vaccination [Internet]. 2022 [cited 25th JULY 2022]. Available from: https://www.cdc.gov/poxvirus/monkeypox/considerations-for-monkeypox-vaccination.html.
[10] C.D.C. Treatment, Information for Healthcare Professionals 2022 [updated 22nd June 2022. Available from: https://www.cdc.gov/poxvirus/monkeypox/treatment.html.
[11] H. Adler, S. Gould, P. Hine, I.B. Snell, W. Wong, C.F. Houlihan, et al., Clinical features and management of human monkeypox: a retrospective observational study in the UK, Lancet Infect. Dis. 22 (8) (2022) 1153-1162.
[12] cidrap. CDC confirms 9 monkeypox cases, all in MSM 2022 [Available from: https://www.cidrap.umn.edu/news-perspective/2022/05/cdc-confirms-9-monkeypox-cases-all-msm.
[13] J. Inigo Martinez, E. Gil Montaltian, S. Jimenez Bueno, F. Martin Martinez, A. Nieto Julià, J. Sanchez Diaz, et al., Monkeypox Outbreak Predominantly Affecting Men Who Have Sex with Men, Madrid, Spain vol. 27, 2022, 2200471, 26 April to 16 June 2022, 27.
[14] AIDSmap, What does the monkeypox outbreak mean for people living with HIV?, Available from: https://www.aidsmap.com/news/jun-2022/what-does-monkeypox-outbreak-mean-people-living-hiv , 2022.
[15] J. Henkin, A. Belfield, C. Milne, N. Brown, Y. Walters, C. Scott, et al., Transmission of monkeypox virus through sexual contact – A novel route of infection, J. Infect. 85 (3) 334-363.
[16] J.F. Thornhill, S. Barkati, S. Walsams, J. Rockstroh, A. Antinori, L.B. Harrison, et al., Monkeypox Virus Infection in Humans across 16 Countries — April-June 2022, 2022.
[17] Some monkeypox patients also have sexually transmitted diseases, CDC says. cnnbc. (2022 June 10) 2022.
[18] Monkeys are Spreading through Sex, but it’s Not an STI. Bloomberg Asia, 2022 26th May 2022.
[19] Let’s Stop HIV Together [Internet]. 2022 [cited 24th July 2022]. Available from: https://www.cdc.gov/stophivtogether/index.html.